Connect with us

Hi, what are you looking for?

The Smart Citizen Report

BREAKING NEWS

Johnson & Johnson expects COVID-19 vaccine data next week

imageStock Markets3 hours ago (Jan 26, 2021 10:40AM ET)

2/2

(C) Reuters. FILE PHOTO: Vials and medical syringe are seen in front of J&J logo in this illustration

2/2

By Manas Mishra and Carl O’Donnell

(Reuters) – Johnson & Johnson (NYSE:JNJ) on Tuesday said it expected to report eagerly-awaited data on its COVID-19 vaccine early next week, and that it would be able to meet the delivery target for doses to countries with which it had signed supply agreements.

Public health officials are increasingly counting on single-dose options like the one being tested by J&J to simplify and boost inoculations given the complications and slower-than-hoped rollout of authorized vaccines from Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc, which require second shots weeks after the first.

The company forecast 2021 profit well above Wall Street estimates, and its shares rose 3.4% to $171.55.

The outlook does not include any contribution from the COVID-19 vaccine, Chief Financial Officer Joseph Wolk said.

Wolk added that pricing of the vaccine would depend on the number of doses secured by countries and organizations.

“We will let the science play out. Once we have the data, obtain regulatory authorization and finalize agreements to supply, we will provide financial updates as warranted,” he said on a conference call.

The U.S. healthcare conglomerate said its medical device unit continued to recover despite the recent surge in COVID-19. The division was hit hard earlier in the pandemic by a decrease in elective and non-urgent procedures like hip and knee replacement as people avoided care or hospitals were forced to suspend such procedures.

Fourth-quarter sales in the unit fell marginally to $6.59 billion.

Adjusted profit of $1.86 per share beat estimates of $1.82 per share, helped by double-digit sales growth of Crohn’s disease drug Stelara and cancer treatment Darzalex.

Stelara sales grew 32% to $2.44 billion, while sales of Darzalex jumped nearly 60% to $1.25 billion.

J&J forecast 2021 adjusted profit of between $9.40 and $9.60 per share, compared with analysts’ estimates of $8.99 per share, according to IBES data from Refinitiv.

Johnson & Johnson expects COVID-19 vaccine data next week

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Join Our Time-Limited Free Subscription! Get Latest Trading Ideas, Business Info and Market Stocks.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

You May Also Like

Editor's Pick

 Going Full Liberal In response to the arrest of a man who walked into a cafe holding a baseball bat and screaming through a megaphone, a...

Editor's Pick

Going Full Liberal The liberal plan?  Get the body count as high as possible to hurt Trump.  These people are disgusting. Last week, the...

Editor's Pick

Going Full Liberal More trouble for creepy Joe. An extensive new survey by Morning Consult of nearly 28,000 registered voters presents some troubling numbers for the...

Editor's Pick

Going Full Liberal Liberal brilliance on full display. New York City appears to have experienced a surge in shootings this week after the New...

Editor's Pick

Going Full Liberal In the past few weeks, demonstrators — mobs, really — have destroyed or defaced the following statues across the United States....

Editor's Pick

Going Full Liberal The Justice Department released Peter Strzok notes from 1/4/2017 regarding the Flynn-Kislyak calls. Last month it was revealed 2020 Democrat presidential...

BREAKING NEWS

U.S. futures, Asian shares open lower ahead of an earnings season with potentially devastating results A historic OPEC++ production cut deal misses even producer...

BREAKING NEWS

Crude oil prices plunged sharply on Thursday, extending losses to a fifth session, amid concerns about the outlook for energy demand. The coronavirus has...

Disclaimer: TheSmartCitizenReport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.

The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

© Copyright 2021,TheSmartCitizenReport.com All Rights Reserved

Join Our Time-Limited Free Subscription! Get Latest Trading Ideas, Business Info and Market Stocks.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!